Gapping up
In reaction to earnings/guidance:
- PSO +8.4%, BOH +5%, KEX +2.4%
Other news:
- PCVX +40.9% (Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate)
- SCHL +11.5% (authorizes repurchase of up to $75 mln in common stock)
- MYOV +8.2% (to be acquired by Sumitovant Biopharma for $27.00 per share in cash)
- MWA +4.3% (increases its quarterly dividend)
- ZNTL +3% (plans to initiate the first study of its collaboration with Pfizer (PFE) on Zentalis' product candidate ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells)
- VRAY +2.3% (Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients)
- MDT +1.6% (announces intention to separate its combined patient monitoring and respiratory interventions businesses)
- SRRK +1.5% (reports New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA)
- MCRB +1.4% (Presents SER-109 ECOSPOR IV Study Data)
Analyst comments:
- CAR +3.5% (upgraded to Overweight from Neutral at JP Morgan)
- NOW +3% (upgraded to Buy from Neutral at Guggenheim)